NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-RM-21-003 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite applications for Microbiome and Metagenomics Centers (MMC) to join the Nutrition for Precision Health consortium (https://commonfund.nih.gov/nutritionforprecisionhealth). The overall goal of the Microbiome and Metagenomics Center (MMC) is to perform microbiome, metagenomics and metatranscriptomics analysis of stool specimens collected in the Nutrition for Precision Health study.
Funding Opportunity RFA-RM-21-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for a Metabolomics and Clinical Assays Center (MCAC) to join the Nutrition for Precision Health Consortium (https://commonfund.nih.gov/nutritionforprecisionhealth). The focus of this center is to (1) generate targeted and non-targeted metabolite profiles and (2) perform or facilitate clinical assays from blood, urine and stool biospecimens.
Funding Opportunity PAR-21-096 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate FOA: PAR-xx-xxxx Independent Clinical Trial Required. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA PAR-xx-xxx Independent Clinical Trial Not Allowed FOA.
Funding Opportunity PAR-21-095 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-nnn.
Funding Opportunity PAR-21-094 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ( PAR-21-095). Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOAPAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)
Funding Opportunity PAR-21-139 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites qualified academic institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and nonprofit private institutions of higher education. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity. The goal of this FOA is to upgrade or create novel biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Targeted projects are the modernization of core facilities and the development of other infrastructure serving an institution-wide research community on a shared basis.
Notice NOT-NS-21-024 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-21-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support applications aimed at: (1) determining whether microbial pathogens represent a causal component ?of Alzheimers disease (AD), (2) establishing mechanisms by which microbial pathogens impact neurodegenerative processes in AD, and (3) informing aspects of future translational studies in AD, including the discovery of candidate therapeutics aimed at regulating pathogen-associated networks and molecules in AD.
Notice NOT-CA-21-030 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-004 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-001 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-TR-21-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for multi-disciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation. Of particular importance, these strategies must be able to be adopted and performed at the primary or secondary care levels by front-line healthcare providers and be readily integrated into their clinical care workflow.
Funding Opportunity RFA-EY-21-001 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-17-003) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-17-004) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization. In addition to experimental approaches, the support provided under this FOA might enable calculations, simulations, computational models, or other mathematical techniques for demonstrating that the signal sources and/or measurement technologies are theoretically capable of meeting the demands of large-scale recording or manipulation of circuit activity in humans or in animal models. The support might also be used for building and testing phantoms, prototypes, in-vitro or other bench-top models in order to validate underlying theoretical assumptions in preparation for future FOAs aimed at testing in animal models.
Funding Opportunity PAR-21-118 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion FOA which utilizes an R61/R33 phased approach.
Funding Opportunity PAR-21-119 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Funding Opportunity PAR-21-108 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provide support and mentorship to outstanding students enrolled in integrated dual degree dental (DDS/DMD) and PhD programs over the transition from predoctoral student to postdoctoral scholar. This phased award program will facilitate completion of predoctoral dual degree dentist scientist training (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable dentist scientists to progress in their research careers. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Notice NOT-ES-21-005 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-015 from the NIH Guide for Grants and Contracts
Notice NOT-HL-21-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-083 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.